Literature DB >> 23054654

Epigenetic aspects of MDS and its molecular targeted therapy.

Jumpei Yamazaki1, Jean-Pierre J Issa.   

Abstract

The term "epigenetics" refers to clonally inherited stable variability in gene expression without underlying genetic changes. There are two well-known molecular mechanisms for epigenetic information: DNA methylation and histone modifications. Epigenetic changes have been recognized in the past decade as critical factors for physiological phenomena such as embryogenesis and the differentiation of normal cells. There is recent interest regarding the involvement of aberrant DNA methylation and histone modifications in mediating altered physiology in cancer. MDS is characterized by epigenetic changes, mutations in epigenetic regulators, and response to DNA methylation inhibitors, suggesting that epigenetic changes are unique features of MDS patients. In this article, recent progress in the understanding of MDS epigenetics and epigenetics-based therapies is reviewed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054654     DOI: 10.1007/s12185-012-1197-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  86 in total

Review 1.  The nucleosome: from genomic organization to genomic regulation.

Authors:  Sepideh Khorasanizadeh
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 2.  Epigenetic therapy of cancer: past, present and future.

Authors:  Christine B Yoo; Peter A Jones
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

Review 3.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

Review 5.  Genomic imprinting: the emergence of an epigenetic paradigm.

Authors:  Anne C Ferguson-Smith
Journal:  Nat Rev Genet       Date:  2011-07-18       Impact factor: 53.242

6.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

7.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Authors:  Jean-Pierre J Issa; Guillermo Garcia-Manero; Francis J Giles; Rajan Mannari; Deborah Thomas; Stefan Faderl; Emel Bayar; John Lyons; Craig S Rosenfeld; Jorge Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

8.  A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.

Authors:  Jharna Datta; Kalpana Ghoshal; William A Denny; Swarna A Gamage; Darby G Brooke; Pasit Phiasivongsa; Sanjeev Redkar; Samson T Jacob
Journal:  Cancer Res       Date:  2009-05-05       Impact factor: 12.701

Review 9.  MLL-rearranged leukemias: insights from gene expression profiling.

Authors:  Scott A Armstrong; Todd R Golub; Stanley J Korsmeyer
Journal:  Semin Hematol       Date:  2003-10       Impact factor: 3.851

Review 10.  The many faces of histone lysine methylation.

Authors:  Monika Lachner; Thomas Jenuwein
Journal:  Curr Opin Cell Biol       Date:  2002-06       Impact factor: 8.382

View more
  14 in total

Review 1.  Small RNA as a regulator of hematopoietic development, immune response in infection and tumorigenesis.

Authors:  Kazuki Okuyama; Jun Ogata; Natsuko Yamakawa; Bidisha Chanda; Ai Kotani
Journal:  Int J Hematol       Date:  2014-04-01       Impact factor: 2.490

2.  Gene body methylation can alter gene expression and is a therapeutic target in cancer.

Authors:  Xiaojing Yang; Han Han; Daniel D De Carvalho; Fides D Lay; Peter A Jones; Gangning Liang
Journal:  Cancer Cell       Date:  2014-09-25       Impact factor: 31.743

Review 3.  Multistep tumorigenesis in peripheral T cell lymphoma.

Authors:  Mamiko Sakata-Yanagimoto
Journal:  Int J Hematol       Date:  2015-01-28       Impact factor: 2.490

Review 4.  DNA methylation in systemic lupus erythematosus.

Authors:  Christian M Hedrich; Katrin Mäbert; Thomas Rauen; George C Tsokos
Journal:  Epigenomics       Date:  2016-11-25       Impact factor: 4.778

5.  Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase.

Authors:  Masayo Yamamoto; Hiroki Tanaka; Yasumichi Toki; Mayumi Hatayama; Satoshi Ito; Lynda Addo; Motohiro Shindo; Katsunori Sasaki; Katsuya Ikuta; Takaaki Ohtake; Mikihiro Fujiya; Yoshihiro Torimoto; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2016-07-05       Impact factor: 2.490

6.  Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.

Authors:  Ryo Shimizu; Tomoya Muto; Kazumasa Aoyama; Kwangmin Choi; Masahiro Takeuchi; Shuhei Koide; Nagisa Hasegawa; Yusuke Isshiki; Emi Togasaki; Chika Kawajiri-Manako; Yuhei Nagao; Shokichi Tsukamoto; Shio Sakai; Yusuke Takeda; Naoya Mimura; Chikako Ohwada; Emiko Sakaida; Tohru Iseki; Daniel T Starczynowski; Atsushi Iwama; Koutaro Yokote; Chiaki Nakaseko
Journal:  Leuk Res       Date:  2016-09-26       Impact factor: 3.156

7.  Expressional changes of genes and miRNA in common megakaryocyte-erythroid progenitors from lower-risk myelodysplastic syndrome.

Authors:  Kazuhiro Maki; Ko Sasaki; Yasunobu Nagata; Fusako Nagasawa; Yuka Nakamura; Seishi Ogawa; Kinuko Mitani
Journal:  Int J Hematol       Date:  2014-07-24       Impact factor: 2.490

8.  Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.

Authors:  Hiroaki Tanaka; Naomi Shimizu; Emi Tougasaki; Chika Kawajiri; Shinichiro Hashimoto; Yusuke Takeda; Shio Sakai; Masahiro Takeuchi; Chikako Ohwada; Emiko Sakaida; Toshiyuki Takagi; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2013-03-22       Impact factor: 2.490

9.  Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.

Authors:  Guillermo Garcia-Manero; Gail Roboz; Katherine Walsh; Hagop Kantarjian; Ellen Ritchie; Patricia Kropf; Casey O'Connell; Raoul Tibes; Scott Lunin; Todd Rosenblat; Karen Yee; Wendy Stock; Elizabeth Griffiths; Joseph Mace; Nikolai Podoltsev; Jesus Berdeja; Elias Jabbour; Jean-Pierre J Issa; Yong Hao; Harold N Keer; Mohammad Azab; Michael R Savona
Journal:  Lancet Haematol       Date:  2019-05-03       Impact factor: 18.959

10.  SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.

Authors:  D Inoue; J Kitaura; H Matsui; H-A Hou; W-C Chou; A Nagamachi; K C Kawabata; K Togami; R Nagase; S Horikawa; M Saika; J-B Micol; Y Hayashi; Y Harada; H Harada; T Inaba; H-F Tien; O Abdel-Wahab; T Kitamura
Journal:  Leukemia       Date:  2014-10-13       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.